TY - JOUR
T1 - Height and weight in children treated for acute lymphoblastic leukemia
T2 - Relationship to CNS treatment
AU - Dalton, Virginia Kimball
AU - Rue, Montse
AU - Silverman, Lewis B.
AU - Gelber, Richard D.
AU - Asselin, Barbara L.
AU - Barr, Ronald D.
AU - Clavell, Luis A.
AU - Hurwitz, Craig A.
AU - Moghrabi, Albert
AU - Samson, Yvan
AU - Schorin, Marshall
AU - Tarbell, Nancy J.
AU - Sallan, Stephen E.
AU - Cohen, Laurie E.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Purpose: We evaluated the long-term effects of treatment on height and weight in children with acute lymphoblastic leukemia (ALL) treated with one of the following three different CNS therapies: intrathecal therapy alone, intrathecal therapy with conventional cranial radiation, or intrathecal therapy with twice-daily radiation. Patients and Methods: Between 1987 and 1995, 618 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for ALL were measured for height and weight at diagnosis, and approximately every 6 months thereafter. Patient height, weight, and body mass index (BMI) were converted to z scores for age and sex using the 2000 Centers for Disease Control and Prevention growth charts for the United States. Results: Children younger than 13 years at diagnosis had a statistically significant decrease in their height z scores and an increase in their BMI z scores, regardless of whether they had received cranial radiation. Young age at diagnosis and increased chemotherapy intensity were major risk factors. Unexpectedly, there was no significant difference in long-term height between children who received radiation and those who did not. Conclusion: Final height is compromised in survivors of ALL The detrimental effects on height occur during therapy without the ability for long-term catch-up growth. Although patients became overweight for height, this seemed to be a result of relative height loss with normal weight gain rather than accelerated weight gain. The type of CNS treatment received did not affect changes in height, weight, or BMI.
AB - Purpose: We evaluated the long-term effects of treatment on height and weight in children with acute lymphoblastic leukemia (ALL) treated with one of the following three different CNS therapies: intrathecal therapy alone, intrathecal therapy with conventional cranial radiation, or intrathecal therapy with twice-daily radiation. Patients and Methods: Between 1987 and 1995, 618 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for ALL were measured for height and weight at diagnosis, and approximately every 6 months thereafter. Patient height, weight, and body mass index (BMI) were converted to z scores for age and sex using the 2000 Centers for Disease Control and Prevention growth charts for the United States. Results: Children younger than 13 years at diagnosis had a statistically significant decrease in their height z scores and an increase in their BMI z scores, regardless of whether they had received cranial radiation. Young age at diagnosis and increased chemotherapy intensity were major risk factors. Unexpectedly, there was no significant difference in long-term height between children who received radiation and those who did not. Conclusion: Final height is compromised in survivors of ALL The detrimental effects on height occur during therapy without the ability for long-term catch-up growth. Although patients became overweight for height, this seemed to be a result of relative height loss with normal weight gain rather than accelerated weight gain. The type of CNS treatment received did not affect changes in height, weight, or BMI.
UR - http://www.scopus.com/inward/record.url?scp=0042887527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042887527&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.03.068
DO - 10.1200/JCO.2003.03.068
M3 - Article
C2 - 12885815
AN - SCOPUS:0042887527
SN - 0732-183X
VL - 21
SP - 2953
EP - 2960
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 15
ER -